

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A23J 3/34</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 93/24020</b> <b>(43) International Publication Date:</b> 9 December 1993 (09.12.93)
<b>(21) International Application Number:</b> PCT/DK93/00182 <b>(22) International Filing Date:</b> 26 May 1993 (26.05.93)  <b>(30) Priority data:</b> 712/92 27 May 1992 (27.05.92) DK  <b>(71) Applicant (for all designated States except US):</b> NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> NIELSEN, Per, Munk [DK/DK]; Rytterstien 29A, DK-3400 Hillerød (DK). HVASS, Peter [DK/DK]; Toftebæksvej 54 st.tv, DK-2800 Lyngby (DK).  <b>(74) Agent:</b> NOVO NORDISK A/S; Patent Department, Novo Allé, DK-2880 Bagsvaerd (DK).		<b>(81) Designated States:</b> AU, CA, JP, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHOD FOR PRODUCTION OF A WHEY PROTEIN HYDROLYZATE AND A WHEY PROTEIN HYDROLYZATE  <b>(57) Abstract</b>  The method for production of a whey protein hydrolyzate comprises the use of a whey protein product produced by acidic precipitation of casein as a starting material and combined with a non-pH-stat hydrolysis. The method provides a well tasting and organoleptically acceptable product with low allergenicity in high yield.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TC	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

**METHOD FOR PRODUCTION OF A WHEY PROTEIN HYDROLYZATE  
AND A WHEY PROTEIN HYDROLYZATE**

The invention comprises a method for production of a whey protein hydrolyzate and the thus produced whey protein hydrolyzate.

5 Many methods for production of a protein hydrolyzate with good organoleptic properties can be carried out with a low yield only. Also, a disadvantage in regard to the prior art whey protein hydrolyzates is the fact that the allergenicity thereof is open to improvement. Thus, it is the purpose of the invention to indicate a method for production of a whey protein hydrolyzate with reduced  
10 allergenicity and with good organoleptic properties, which can be carried out with a relatively high yield.

Surprisingly, according to the invention it has been found that a selection of a specified starting material in combination with a non-pH-stat hydrolysis provides a process for production of a low allergenicity and organoleptically acceptable  
15 product in high yield.

Thus, the method according to the invention for production of a whey protein hydrolyzate is characterized by the fact

- 1) that whey protein produced by acidic precipitation of casein is mixed with water to a slurry with a protein content up to about 20%, preferably up to 12%,
- 20 2) that a heat treatment to a temperature above 60°C is carried out,
- 3) that the mixture from step 2) is proteolytically hydrolyzed by means of at least one protease, by means of a non-pH-stat method to a DH of between 15 and 35%, and
- 4) that the hydrolysis is terminated by inactivation of the enzyme(s).

25 A whey protein hydrolyzate with a composition similar to the whey protein hydrolyzate produced by means of the method according to the invention is described in US 4,427,658.

Also, EP 226221 describes a whey protein hydrolyzate, which however, in contradistinction to the whey protein hydrolyzate produced by means of the method according to the invention is free from lactose and is produced by means of the pH-stat techniques.

5 Also, US 4,293,571, EP 321603 and EP 322589 describe a whey protein hydrolyzate, which is produced by hydrolysis with subsequent heat treatment, in contradistinction to the whey protein hydrolyzate produced by means of the method according to the invention, i.e. by means of heat treatment with subsequent hydrolysis. The high values of the degree of hydrolysis which can be obtained  
10 according to the invention, cannot be obtained with the prior art methods.

EP 65663 describes a whey protein hydrolyzate, which is produced without heat treatment before the hydrolysis, in contradistinction to the method according to the invention.

In Research Disclosure, August 1981 no. 20826 a method similar to the  
15 method according to the invention is described. However, the prior art method is restricted to blood as the starting material, and also, the prior art method is performed by means of the pH-stat method.

To the best of the applicant's knowledge, all prior art methods for production of a whey protein hydrolyzate give rise to a whey protein hydrolyzate with  
20 an unacceptable taste and a relatively high allergenicity. The whey protein hydrolyzate according to the invention has a markedly agreeable taste and a remarkable low allergenicity. Also, in relation to many of the prior art methods for production of whey protein hydrolyzate the end product is obtained in a low yield and/or at high production cost.

25 A preferred embodiment of the method according to the invention comprises that the slurry in step 1) has a protein content of 7-12%. In this manner the equipment is utilized optimally, and also, the viscosity is not too high for handling.

A preferred embodiment of the method according to the invention  
30 comprises that the pH adjustment in step 3) is carried out by means of  $\text{Ca(OH)}_2$  and/or KOH. In this manner a better taste is obtained, and also, a favorable mineral

distribution in the final product is obtained. Also, sodium carbonate or sodium phosphate can be used for pH adjustment in order to precipitate the  $\text{Ca}^{++}$  in the raw whey protein product.

A preferred embodiment of the method according to the invention  
5 comprises that the hydrolysis in step 3) is carried out to a DH of between 20-35. In this manner a product with excellent organoleptic properties is obtained.

A preferred embodiment of the method according to the invention comprises that a protease producible by means of *B. licheniformis*, preferably Alcalase<sup>®</sup>, and/or a protease producible by means of *B. subtilis*, preferably  
10 Neutrase<sup>®</sup>, and/or trypsin is used as proteolytic enzyme(s). It is especially preferred to use Alcalase<sup>®</sup> (with a high pH optimum) first, and then Neutrase<sup>®</sup> (with a lower pH optimum). This method is especially well suited to the non-pH-stat-method used according to the invention.

A preferred embodiment of the method according to the invention  
15 comprises that the mixture from step 3) or 4) is separated on an ultrafiltration/-microfiltration unit with cut-off value above 10,000, preferably above 50,000, the permeate constituting the protein hydrolyzate. In this manner a very high flux is obtainable.

A preferred embodiment of the method according to the invention  
20 comprises that the inactivation of the enzyme(s) (step 4)) is carried out by heat treatment. This inactivation is especially well suited in case the pH of the final protein hydrolyzate is supposed to be relatively high (around neutrality).

A preferred embodiment of the method according to the invention comprises that the inactivation of the enzyme(s) (step 4)) is carried out by acid  
25 treatment. This inactivation is especially well suited in case the pH of the final protein hydrolyzate is supposed to be relatively low (acidic).

A preferred embodiment of the method according to the invention comprises that the mixture at the end of step 3) or step 4) is treated with activated carbon for more than 5 minutes at a temperature, which is preferably between 50  
30 and 70°C in an amount corresponding to between 1 and 5% carbon, calculated in

relation to dry matter content, and that the activated carbon is removed. In this manner the flavor is improved.

A preferred embodiment of the method according to the invention comprises that after step 4) a concentration is carried out by nanofiltration/hyper-  
 5 filtration/reverse osmosis at a temperature, which is preferably between 50 and 70°C and/or evaporation, whereafter the retentate is collected as the protein hydrolyzate solution. By means of the nanofiltration a desalination can be carried out by proper selection of the membrane; besides nanofiltration/hyper-filtration/reverse osmosis is an inexpensive way for removal of water. Evaporation has the advantage of obtaining  
 10 a high dry matter content in the concentrate before drying.

A preferred embodiment of the method according to the invention comprises that the protein hydrolyzate solution from step 4) is spray-dried to a water content below 6.5%. In this manner a stable product is obtained, both microbially and organoleptically.

15 Also, the invention comprises a whey protein hydrolyzate produced by means of the method according to the invention, and characterized by the fact that it exhibits the following molecular weight (MW) distribution

		<u>Weight-%</u>
	MW > 5000	< 0.5
20	1500 < MW < 5000	5 - 15
	500 < MW < 1500	40 - 60
	MW < 500	40 - 60

whereby the content of free amino acids < 15. Surprisingly, it has been found that in this embodiment a whey protein hydrolyzate with an extraordinary low antigenicity  
 25 is obtained. Reference is made to Example 1. This extraordinary low antigenicity corresponds to a substantial reduction of the allergenicity.

Also, the invention comprises a whey protein hydrolyzate which is characterized by the fact that it is produced on the basis of a starting material which is whey from acidic precipitated casein, that it exhibits the following MW distributions.

	<u>Weight-%</u>
MW > 5000	< 0.5
1500 < MW < 5000	5 - 15
500 < MW < 1500	40 - 60
5 MW < 500	40 - 60

whereby the content of free amino acids < 15, and that it exhibits a reduction of antigenicity compared to Lacprodan 80 of at least  $10^5$  times.

The MW distribution of peptides in protein hydrolyzates, as indicated above, is determined as follows.

#### 10 1. Principle

The sample is diluted, filtered and injected into a liquid chromatographic system, operating in the Gel Permeation Chromatography (GPC) mode. this separation technique utilizes a liquid flow through a column filled with porous particles, having pores with a well-defined pore diameter. When a solution  
 15 of peptides, having different molecular sizes passes through the column, the small peptides will be able to flow into the pores while the larger peptides will be excluded from the pores. Thus, the peptides in a solution will be separated according to molecular size (and molecular weight), as the larger peptides will be eluted faster from the column than the smaller peptides. A detector at the column outlet  
 20 continuously measures the effluent. The chromatographic system is calibrated by means of peptides with known MW.

#### 2. Chromatographic equipment

- 2.1 HPLC system consisting of
  - High Pressure pump, Waters M 510, Flow rate 0.7 ml/min
  - 25 Injector, Waters WISP M 710
  - Detector, Waters M 440, with wave length extension to 214 nm.
- 2.2 GPC column, 3 x TSK G 2000 SWXL, 7.8 mm x 300 mm, connected in series and operated at ambient temperature.

- 2.3 Integration/data processing, Waters 820 MAXIMA SIM chromatography data system with 810/820 GPC option.

### 3. Reagents

- 3.1 Phosphate buffer,  $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$
- 5 3.2 Ammonium chloride,  $\text{NH}_4\text{Cl}$
- 3.3 Trifluoroacetic acid (TFA),  $\text{CF}_3\text{COOH}$
- 3.4 Acetonitrile,  $\text{CH}_3\text{CN}$
- 3.5 Mobile phase:  
0.05 M phosphate buffer / 0.5 M ammonium chloride solution containing  
10 0.1% TFA and 25% acetonitrile

### 4. Description

- 4.1 Calibration
- 15 The chromatographic system is calibrated by means of injections of numerous peptide standards with known MW. The MW of each standard is plotted semilogarithmic versus the observed volume of mobile phase needed to elute the peptide from the column. By a least squares calculation, the best fitting 3rd order polynomial is calculated. This curve represents the calibration curve.
- 4.2 Analysis
- 20 The sample is diluted/dissolved in mobile phase to approx. 5 mg/ml. The solution is filtered through a  $22\ \mu\text{m}$  filter and  $20\ \mu\text{l}$  is used for injection into the chromatograph. The detector response versus elution volume is recorded. The recorded curve - the chromatogram - shows the actual MW distribution of the sample. To allow for calculations as to  
25 accumulated weight distribution and average MW calculations, the chromatogram is divided into small time (and elution volume) segments - each segment characterized by the elution volume and the area of the chromatogram over the time interval.



5. Calculation

Results are given in terms of weight and number average MW.

$$\bar{M}_w = \frac{\sum_i (A_i \cdot M_{w,i})}{\sum_i A_i}, \quad \bar{M}_n = \frac{\sum_i A_i}{\sum_i (A_i / M_{w,i})}, \text{ where}$$

$\bar{M}_w$  : Weight average MW

$\bar{M}_n$  : Number average MW

10  $A_i$  : Area of chromatogram for each segment, measured as the accumulated detector response over each time interval.

$M_{w,i}$  : The corresponding MW for each segment. The value is calculated by means of the calibration curve, using the average elution volume over the time interval.

15 The method according to the invention and the whey protein according to the invention will be illustrated in the following example.

**EXAMPLE 1**Feed

The starting material is spray-dried whey protein concentrate (the  
20 commercial product Lacprodan 75CV, obtained from Danmark Protein A/S, Denmark) containing approx. 80% protein calculated as dry matter. This starting material is obtained from production of acid precipitated casein by ultrafiltration/diafiltration, neutralizing and drying.

Mixing

The starting material is diluted with deionized water to a protein content of 8%.

Heat treatment

- 5            Pasteurisation is carried out by heating to 85°C, holding for 5 minutes and cooling to 53°C.

pH adjustment

pH is adjusted to 8.0 with  $\text{Ca}(\text{OH})_2$ .

Hydrolysis

- 10           Temperature 53°C.  
Enzymes: Alcalase® 2.4 L. Dosage 2.2%  
          Neutrase® 0.5L. Dosage 1.1%

Hydrolysis for 18 hours. Increase in osmolality was 200 mOsm/kg.

Ultrafiltration step

- 15           The mixture is filtered by means of a Millipore Pellicon System with PTTK 30,000 NMWL membranes. Temperature 50°C.

Inactivation

The permeate from the ultrafiltration step is heated to 85°C for 3 minutes in order to inactivate the enzymes.

20 Drying

The product is freeze dried.

The MW distribution of the freeze dried product appears from the following table.

	<u>Weight-%</u>
MW > 5000	0.1
1500 < MW < 5000	6.6
500 < MW < 1500	47.7
5 MW < 500	45.6

whereby the content of free amino acids < 15

Also, reference is made to Fig. 1, which shows the MW distribution of the freeze dried product.

Antigenicity tests were carried out, as indicated in the following.

#### 10 Evaluation of the antigenicity of whey protein hydrolyzates by ELISA-test

##### 1. Principle

The antigenicity of a whey protein hydrolyzate is tested by a modified double antibody sandwich ELISA. In this technique an antibody (catching antibody; from rabbit) is coated to a microtitre well. Then the sample containing the antigen  
15 is added. Subsequently an antibody (detecting antibody; from guinea pig) is added to form the sandwich antibody-antigen-antibody. Quantitation is carried out by reaction with a peroxidase-labelled antibody to guinea pig (from rabbit) and addition of OPD (O-phenylenediamine hydrochloride). The yellow colour, that develops, is measured in an ELISA reader.

##### 20 2. Description

The following samples were tested :

- a) Lacprodan 80 - bovine whey protein (spray-dried powder; 77% protein)
- b) Product from Example 1 - whey protein hydrolyzate (freeze-dried powder; 78.1% protein)

Each well of a microtitre plate is coated with catching antibody (rabbit antiserum to bovine whey protein; DAKO Z183) and washed. The samples are dissolved in buffer solution to a starting concentration of 4 µg/ml of Lacprodan 80 and 100 mg/ml of the product from Example 1. Twofold dilutions of the samples are  
5 added in duplicate to separate wells and incubated overnight at 4°C. Subsequently a washing is performed. To each well is added detection antibody (guinea pig antiserum to bovine whey protein; prepared by means of Lacprodan 80 as protein source) and washed. To each well is added peroxidase conjugated rabbit antiserum to guinea pig serum (DAKO P141) and washed. The wells are developed by addition  
10 of OPD (O-phenylenediamine hydrochloride) and the yellow colour is measured by reading the absorbance at 492 nm.

### 3. Result

The result is given in Fig. 2, showing the measured absorbance at 492 nm for different protein concentrations in µg/ml. From the curves it appears that the  
15 product from Example 1 has a remarkable reduced antigenicity. By comparing the protein concentrations to give similar absorbance, the reduction in antigenicity can be estimated: The antigenicity of the product from Example 1 is reduced approximately  $1.7 \times 10^5$  times compared to Lacprodan 80.

### Evaluation of the antigenicity of whey protein hydrolyzates by testing for reactivity 20 with milk specific IgE

In this test the reduction in antigenicity is measured relatively to skim milk powder.

#### **Test sera**

Two serum samples from children allergic to cow's milk were used: KG  
25 and LV.

Both of the two donors were highly allergic to cow's milk as proven by DBPCFC. Sera from the donors had previously been tested for specific IgE to cow's milk, and were found to be positive.

As negative control serum was used a "1000-donor pool", prepared from sera without IgE reactivity to ordinary inhalation allergens (Poulsen & Weeke, 1985).

### Allergens

- 5 1. Whey protein hydrolyzate produced according to this example.
2. Commercial mother milk substitute, Nutramigen, 13.0% protein
3. Skim milk powder, 37% protein

### Inhibition experiments

By means of Maxisorp RAST (Poulsen et al., 1989) dose-response  
10 curves for varying concentrations of skim milk were made. A concentration of 1 mg/ml was used. Serum dilution experiments demonstrated that both sera could be diluted 1:10 for inhibition experiments, giving a final concentration of 1:20.

All antigens were run in dilution series giving final concentrations of 50 mg/ml, 5 mg/ml, 500 µl/ml, 50 µl/ml, 5 µl/ml and 500 ng/ml. Inhibition is expressed  
15 as

$$\% \text{ inhibition} = 100 * \frac{\text{response}_{\text{uninhib}} - \text{response}_{\text{inhib}}}{\text{response}_{\text{uninhib}} - \text{response}_{\text{control}}}$$

The inhibitory activities of the hydrolyzed products were compared and  
20 expressed relative to skim milk by calculating the horizontal distance between inhibition curves for the same serum. As inhibition curves were not always parallel, this distance was calculated as close as possible to 50% inhibition.

### Results

Table 1. IgE reactivity to the test products. The results are expressed in relation to skim milk powder

Antigen	% protein	Serum KG	Serum LV
Skim milk powder	37.0	1	1
Nutramigen	13.0	$< < 2.8 \cdot 10^{-5}$	$1.5 \cdot 10^{-4}$
Product from Example 1	78.1	$< < 4.7 \cdot 10^{-6}$	$1.9 \cdot 10^{-5}$

This test also shows a very low antigenicity of the test product. It has been found that the IgE reactivity of the test product is even lower than the IgE reactivity of a well established commercial hypoallergenic product (Nutramigen). Further, if the difference in protein between Nutramigen and the test product is considered the reduction of antigenicity of the test product can be estimated to be at least 60 times better than Nutramigen.

### References

1. Poulsen, L.K. & Weeke, B.  
Aluminum Hydroxide adsorbed Allergens used in modified RAST (Al-RAST)  
Allergy, 40,: 405 - 416 (1985)
2. Poulsen, L.K.; Pedersen, M.F.; Malling, H.-J.; Soendergaard, I. & Weeke, B.  
Maxisorp RAST. A sensitive method for detection of absolute quantities of antigen-specific human IgE.  
Allergy, 44: 173 - 189 (1989)

## CLAIMS

1. Method for production of a whey protein hydrolyzate, characterized by the fact
  - 1) that whey protein produced by acidic precipitation of casein is mixed with water  
5 to a slurry with a protein content up to about 20%, preferably up to 12%,
  - 2) that a heat treatment to a temperature above 60°C is carried out,
  - 3) that the mixture from step 2) is proteolytically hydrolyzed by means of at least one protease, by means of a non-pH-stat method to a DH of between 15 and 35%, and
  - 10 4) that the hydrolysis is terminated by inactivation of the enzyme(s).
2. Method according to Claim 1, characterized by the fact that the slurry in step 1) has a protein content of 7-12%.
3. Method according to Claims 1 - 2, characterized by the fact that a pH adjustment in step 3) is carried out by means of  $\text{Ca(OH)}_2$  and/or KOH.
- 15 4. Method according to Claims 1 - 3, characterized by the fact that the hydrolysis in step 3) is carried out to a DH of between 20-35%.
5. Method according to Claims 1 - 4, characterized by the fact that a protease producible by means of *B. licheniformis*, preferably Alcalase®, and/or a protease producible by means of *B. subtilis*, preferably Neutrase®, and/or trypsin is  
20 used as proteolytic enzyme(s).

6. Method according to Claims 1 - 5, characterized by the fact that the mixture from step 3) or 4) is separated on an ultrafiltration/microfiltration unit with cut-off value above 10,000, preferably above 50,000, the permeate constituting the protein hydrolyzate.
- 5 7. Method according to Claims 1 - 6, characterized by the fact that the inactivation of the enzyme(s) (step 4)) is carried out by heat treatment.
8. Method according to Claims 1 - 6, characterized by the fact that the inactivation of the enzyme(s) (step 4)) is carried out by acid treatment.
9. Method according to Claims 1 - 8, characterized by the fact that the  
10 mixture at the end of step 3) or step 4) is treated with activated carbon for more than 5 minutes at a temperature, which is preferably between 50 and 70°C in an amount corresponding to between 1 and 5% carbon, calculated in relation to dry matter content, and that the activated carbon is removed.
10. Method according to Claims 1 - 9, characterized by the fact that after  
15 step 4) a concentration is carried out by nanofiltration/hyperfiltration/reverse osmosis at a temperature, which is preferably between 50 and 70°C and/or evaporation, whereafter the retentate is collected as the protein hydrolyzate solution.
11. Method according to Claims 1 - 10, characterized by the fact that the protein hydrolyzate solution from step 4) is spray-dried to a water content below  
20 6.5%.
12. Whey protein hydrolyzate, characterized by the fact that it is produced according to Claims 1 - 11, and that it exhibits the following MW distributions.



15

	<u>Weight-%</u>
MW > 5000	< 0.5
1500 < MW < 5000	5 - 15
500 < MW < 1500	40 - 60
5 MW < 500	40 - 60

whereby the content of free amino acids < 15.

13. Whey protein hydrolyzate, characterized by the fact that it is produced on the basis of a starting material which is whey from acidic precipitated casein, that it exhibits the following MW distributions

10	<u>Weight-%</u>
MW > 5000	< 0.5
1500 < MW < 5000	5 - 15
500 < MW < 1500	40 - 60
MW < 500	40 - 60

15 whereby the content of free amino acids < 15, and that it exhibits a reduction of antigenicity compared to Lacprodan 80 of at least  $10^5$  times.

1/2




FIG. 1

SUBSTITUTE SHEET

2/2




FIG. 2

UBSTITUTE SHEET

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 93/00182

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC5: A23J 3/34 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols)		
IPC5: A23J		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO, A1, 9113554 (NOVO NORDISK A/S), 19 Sept 1991 (19.09.91), claims 3,6 and 7  --	1-13
X	WO, A1, 9110369 (TESSENDERLO CHEMIE N.V.), 25 July 1991 (25.07.91), page 9, line 3 - line 4; page 9, line 29 - line 34; page 14, line 24 - line 31  --	1-13
Y	US, A, 4427658 (JEAN-LOUIS MAUBOIS ET AL), 24 January 1984 (24.01.84), column 7, line 30 - line 55; column 13, line 6 - line 26  --	1-13
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
26 August 1993		31 -08- 1993
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer  Kerstin Boije Janson Telephone No. +46 8 782 25 00

Form PCT/ISA/210 (second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 93/00182

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP, A1, 0274946 (LABORATOIRE ROGER BELLON), 20 July 1988 (20.07.88), abstract --	1-13
Y	EP, A1, 0065663 (MILES LABORATORIES INC.), 1 December 1982 (01.12.82), page 9, line 1 - line 5, claims 1,5-6 --	1-13
P,X	WO, A1, 9221248 (DANMARK PROTEIN A/S), 10 December 1992 (10.12.92), claims 1,6 --	1-13
P,X	WO, A1, 9304593 (TEAGASC, THE AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY), 18 March 1993 (18.03.93), page 8, line 23 - line 28, claims 1,5,7 --	1-13
P,A	WO, A1, 9211771 (NOVO NORDISK A/S), 23 July 1992 (23.07.92), claims 1,9 -- -----	1-13

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

30/07/93

International application No.  
PCT/DK 93/00182

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9113554	19/09/91	EP-A- 0518999	23/12/92
WO-A1- 9110369	25/07/91	BE-A- 1003298 EP-A- 0511970	18/02/92 11/11/92
US-A- 4427658	24/01/84	AU-B- 535601 AU-A- 5966780 CA-A- 1150564 EP-A,B- 0022019 SE-T3- 0022019	29/03/84 08/01/81 26/07/83 07/01/81
EP-A1- 0274946	20/07/88	DE-A- 3778141 FR-A,B- 2608051 JP-A- 63258599	14/05/92 17/06/88 26/10/88
EP-A1- 0065663	01/12/82	JP-A- 57194753 JP-B- 58054786	30/11/82 06/12/83
WO-A1- 9221248	10/12/92	AU-A- 1882792	08/01/93
WO-A1- 9304593	18/03/93	AU-A- 2468292	05/04/93
WO-A1- 9211771	23/07/92	NONE	

Form PCT/ISA/210 (patent family annex) (July 1992)